

1 **Circulating Levels of Angiotensinogen, Sex, and Hormone Therapy - The Multi-Ethnic**
2 **Study of Atherosclerosis (MESA)**

3 Angiotensinogen, sex, and sex hormones

4 Karita C. F. Lidani, MD, MSc, PhD^{a,#}, Patrick J. Trainor, PhD, MS, MA^{b,c,#}, Robert Buscaglia,
5 PhD^d, Kristoff Foster, MD, MA^a, Sophia Jaramillo^b, Kirolos Michael^{1a,e}, Alexander Pete Landry^a,
6 Erin D. Michos, MD, MHS^f, Pamela Ouyang, MBBS^g, Erin S. Morgan^h, Sotirios Tsimikas,
7 MD^{h,i}, Andrew P. DeFilippis, MD, MSc^a

8

9 *# These authors shared the first authorship.*

10

11 **Total word count: 5000**

12

13 ^a Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical
14 Center, Nashville, Tennessee

15 ^b Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, New
16 Mexico

17 ^c Molecular Biology and Interdisciplinary Life Sciences Program, New Mexico State University,
18 Las Cruces, New Mexico

19 ^d Department of Mathematics and Statistics, Northern Arizona University, Arizona

20 ^e Meharry Medical College, Nashville, Tennessee

21 ^f Division of Cardiology, Department of Medicine, Johns Hopkins University School of
22 Medicine, Baltimore, Maryland

1 ^g Institute for Clinical and Translational Research, Johns Hopkins University School of
2 Medicine, Baltimore, Maryland

3 ^h Ionis Pharmaceuticals, Carlsbad, California

4 ⁱ Division of Cardiovascular Medicine, University of California-San Diego, La Jolla, California

5

6

7 **Address for correspondence:**

8 Andrew P. DeFilippis, MD, MSc

9 Vanderbilt University Medical Center

10 1215 21st Avenue South

11 MCE 5th Floor, North Tower

12 Nashville, TN 37232

13 Telephone: 1-615-936-1345

14 Email: andrew.defilippis@vumc.org

15

16

17

18

19

20

21

22

1 **ABSTRACT**

2 **Background:** Angiotensinogen, the unique precursor of all angiotensin hormones of the Renin-
3 Angiotensin-Aldosterone System (RAAS), is now a potential target in a novel pharmacological
4 approach to hypertension. Investigating the factors that influence angiotensinogen levels,
5 including sex hormones, may have important therapeutic implications.

6
7 **Methods:** Plasma angiotensinogen and sex hormones levels were measured in 5,171 Multi-
8 Ethnic Study of Atherosclerosis (MESA) participants. Linear models were employed to
9 determine the associations of angiotensinogen with sex hormones, and mediation analysis was
10 performed to evaluate the effect of HT on blood pressure (BP) and hypertension through
11 angiotensinogen.

12
13 **Results:** Angiotensinogen levels were significantly higher in postmenopausal women receiving
14 HT (n=760) compared to women not receiving HRT (n=1,675) and in men (n=2,736). A positive
15 association was present between angiotensinogen and estrogen levels that differed in magnitude
16 between sexes and by HT status among postmenopausal women (women on HT: $r=0.44$, $p<$
17 0.0001 ; women not on HT: $r=0.09$, $p=0.0002$; and men: $r=0.07$, $p=0.0003$). The type of HT
18 formulation (estrogen or estrogen/progesterone) and its duration of use did not significantly
19 affect angiotensinogen levels. HT indirectly increased systolic BP ($\beta=1.24$) and the odds of
20 hypertension (OR=1.065) through its effect of increasing angiotensinogen.

21
22 **Conclusions:** A positive association was present between angiotensinogen and estrogen levels
23 that differed by HT status. HT impacts systolic BP and hypertension indirectly by increasing

1 angiotensinogen. This study underscores the role of angiotensinogen in hypertension, and the
2 complex relationship between HT and hypertension.

3

4 **KEYWORDS:** angiotensinogen, estradiol, hormone therapy, Renin-Angiotensin-Aldosterone
5 System

6

7 **INTRODUCTION**

8 Angiotensinogen is the liver-derived protein precursor of all angiotensin (Ang) peptides of the
9 renin-angiotensin-aldosterone system (RAAS) including Ang I and Ang II ¹⁻³. The RAAS is
10 critical to the pathology of hypertension. Therapeutics that target the downstream metabolism
11 and reception of metabolites of angiotensinogen are proven to improve clinical outcomes for
12 patients with hypertension, and to reduce the risk of heart failure and myocardial infarction ⁴⁻⁶.
13 However, therapies targeting the metabolism or reception of Ang peptides derived from
14 angiotensinogen often lead to a compensatory pathway that limits therapeutic efficacy as
15 monotherapy ². This necessitates the use of a combination with other classes of drugs to achieve
16 adequate blood pressure control in many patients.

17

18 Angiotensinogen is produced primarily by the liver, but the other components of the RAAS
19 pathway are mainly active in the kidney. Angiotensinogen is now a target of therapy in phase 1
20 and 2 trials. It is proposed that targeting angiotensinogen may optimally inhibit the RAAS
21 pathway and provide more effective and possibly safer alternative by inhibiting angiotensinogen
22 in the liver instead of the kidney ^{7,8}.

23

1 Although angiotensinogen plays an essential role in regulating RAAS, little is known about key
2 determinants of angiotensinogen plasma levels. Estrogen may be a significant contributor to
3 expression and activity of RAAS components through several pathways⁹⁻¹¹. Previous studies
4 have demonstrated that circulating levels of angiotensinogen are related to sex^{12,13}, and that the
5 administration of exogenous estrogen to premenopausal women in contraceptive formulations¹⁴
6 and to postmenopausal women as HT¹⁵⁻¹⁷ increases plasma concentrations of circulating
7 angiotensinogen. However, most of these studies are limited by small sample size and were
8 conducted in exclusively normotensive women.

9
10 The effect of natural and supplemental estrogen on angiotensinogen levels and the factors
11 underlying how sex and sex hormones impact angiotensinogen levels remains poorly understood.
12 The current study aimed to better delineate the complex interactions between sex, estrogen, and
13 HT with circulating plasma levels of angiotensinogen and their effect on blood pressure/
14 hypertension in a community-dwelling multi-ethnic cohort.

15

16 **METHODS**

17 **Study participants and design**

18 The Multiethnic Study of Atherosclerosis (MESA) enrolled 6,814 participants (3,601 women and
19 3,213 men) with no-known clinical atherosclerotic cardiovascular disease of four ethnic
20 backgrounds (White, Chinese, Black, and Hispanic), with age between 45-84 years from six
21 communities in the United States (Forsyth County, NC; Northern Manhattan and the Bronx, NY;
22 Baltimore, MD; St. Paul, MN; Chicago, IL; and Los Angeles County, CA). The design of the
23 study has been described in detail in an earlier publication¹⁸. An ancillary study was conducted

1 by our group that measured angiotensinogen levels in MESA participants who were not included
2 in the MESA-1000. The MESA-1000 is a random sample of approximately 1,000 participants
3 that has undergone additional tests using baseline blood samples. To minimize depletion of these
4 specimens, ancillary studies exclude the MESA-1000 participants, unless otherwise justified.
5 Therefore, this study included 5,786 participants. Medical history, laboratory data, and
6 anthropometric measurements were ascertained as described previously^{18,19}. The study was
7 approved by the institutional review boards of the participating institutions, and all participants
8 gave written informed consent.

9
10 Our study population (**Figure 1**) consisted of all men and postmenopausal women who had
11 plasma angiotensinogen levels and sex hormones measured at baseline (n=5,292). Measured sex
12 hormones included total testosterone, dehydroepiandrosterone (DHEA), and estradiol (E2).
13 Additionally, sex hormone binding globulin (SHBG) was measured given its role in transporting
14 hormones in circulation. We sequentially excluded 97 pre-menopausal women, and 24 women
15 with missing information on HT use. Our analytical sample was composed of 2,435
16 postmenopausal women and 2,736 men.

17
18 Menopausal status was determined through an algorithm developed using answers to a series of
19 self-reported questions that included age, age at menopause, history of surgical menopause and
20 age at surgical menopause as compared to age (**Supplemental Figure 1**)²⁰. Indeterminate
21 menopausal women were not included in this analysis. Women were considered postmenopausal
22 if they were older than 55 years of age or had undergone a bilateral oophorectomy and/or self-
23 reported being postmenopausal or having an absence of menstrual periods in the preceding year

1 ²⁰. HT consisted of estrogen alone (Premarin or Estratab) (n = 251, 33.0%) or estrogen with
2 progesterone (Premarin plus Provera, Estratab plus Provera, Prempro, or Premphase) (n = 98,
3 12.9%), while 54.1% (n = 411) had no data on the type of HT. Time duration of HT use ranged
4 from 0 to 49 years (Median = 10.0 years).

6 **Laboratory measurements**

7 Circulating angiotensinogen levels and sex hormones were measured at the baseline (Exam 1)
8 visit of the included MESA participants. Angiotensinogen measurements were made using an
9 enzyme-linked immunoassay that has been described previously ⁷ and was executed by Medpace
10 Reference Labs (Cincinnati, Ohio). Briefly, the coating antibody was rabbit anti-human
11 immunoglobulin monoclonal antibody (IBL-America, Minneapolis, Minnesota). Total
12 angiotensinogen (including intact angiotensinogen and des[Ang I] angiotensinogen) was then
13 detected from 1:10,000 diluted EDTA plasma with horseradish peroxidase mouse anti-human
14 angiotensinogen monoclonal Fab' fragment (IBL-America). A standard curve was generated for
15 quantitation using purified human angiotensinogen. The coefficient of variation was observed to
16 be 9% with an analytical range of 13.9 µg/mL to 75.9 µg/mL.

17
18 Endogenous sex hormone levels were measured from fasting serum samples at the University of
19 Massachusetts Medical Center in Worcester, MA. The assays and kits used to measure the
20 hormone levels were an ultrasensitive radioimmunoassay kit for E2 (Diagnostic System
21 Laboratories, Webster, TX), radioimmunoassay kits for total testosterone and DHEA and a
22 chemiluminescence enzyme immunometric assay using Immulite kits for SHBG (Diagnostic

1 Products Corporation, Los Angeles, CA)²⁰⁻²³. The intra-assay coefficients of variation for total
2 testosterone, SHBG, DHEA, and E2 were 12.3%, 9.0%, 11.2%, and 10.5%, respectively.

3

4 **Other covariates**

5 Covariates were obtained from standardized questionnaires, physical exam, and laboratory
6 measures at study visit 1 as previously reported^{18,19}. Age, race/ethnicity, smoking status, alcohol
7 history, and age at menopause were self-reported. A medication inventory determined
8 medication use including use of HT and antihypertensive medications at visit 1 (baseline).
9 Diabetes was assessed by self-reported physician diagnosis, a fasting glucose level of ≥ 126
10 mg/dL, or hypoglycemic medication use. Height and weight, measured using standardized
11 procedures, were used to calculate body mass index (BMI). Prevalent hypertension was defined
12 as systolic blood pressure (BP) >130 mm Hg, diastolic BP >80 mm Hg, or hypertension
13 medication use at examination 1 (baseline).

14

15 **Statistical analysis**

16 The distribution of cohort characteristics was determined within each sex, including the use of
17 HT in postmenopausal women. Median and quartile values (25th and 75th percentiles) of
18 circulating angiotensinogen levels were determined by sex, race/ethnicity, and HT in
19 postmenopausal women.

20

21 To determine the relationship between circulating angiotensinogen levels and sex by HT, an un-
22 adjusted linear model was estimated by regressing levels of angiotensinogen on sex by HT and
23 estradiol levels. This model was then refitted to incorporate other covariates that had univariable

1 R^2 values greater than 0.025 [race/ethnicity, BMI, total cholesterol, high-sensitivity C-reactive
2 protein (hs-CRP), total testosterone, DHEA, and SHBG). Un-adjusted and adjusted linear models
3 set men as the reference group, and each analyte was log-transformed and then scaled to have
4 mean zero and standard deviation 1. The model coefficients thus reflect a one standard deviation
5 change.

6
7 To investigate the potential mediating role of angiotensinogen in the relationship between HT
8 use and blood pressure/ hypertension, a mediation analysis was conducted to delineate: (1) the
9 direct effect of HT on blood pressure/ hypertension unrelated to angiotensinogen; and (2) the
10 indirect effect of HT on blood pressure/hypertension mediated by angiotensinogen. Regression
11 models were adjusted for age, BMI, race/ethnicity, and smoking history, while the use of any
12 hypertension medication was included as a covariate only for the analysis of blood pressure.

13
14 The analyses reported in the current work were conducted using the R statistical language ²⁴
15 (version 4.0.2) and the following packages: *ppcor* ²⁵, *boot* ²⁶, *emmeans* ²⁷, *dplyr* ²⁸, *ggplot2* ²⁹,
16 and *mediation* ³⁰.

17
18 **RESULTS**
19 Baseline demographics of the 5,171 participants are reported in **Table 1**, stratified by sex and the
20 use of HT in postmenopausal women. Across all race/ethnicity groups, median angiotensinogen
21 levels were highest in postmenopausal women on HT, followed by women participants not on
22 therapy, followed by men (Medians: 36.0 $\mu\text{g/mL}$, 20.7 $\mu\text{g/mL}$, and 18.3 $\mu\text{g/mL}$, respectively)
23 (**Figure 2**). The most pronounced relative difference across race / ethnicity in angiotensinogen

1 levels was observed in the ratio between White and Chinese individuals. Postmenopausal White
2 women on HT have an angiotensinogen ratio of 1.26 (95% CI of 1.15-1.38); followed by
3 postmenopausal white women not on HT (ratio = 1.10 and 95% CI of 1.05-1.16); and men (ratio
4 = 1.06 and 95% CI of 1.02-1.10) as compared to Chinese women and men (**Figure 2,**
5 **Supplemental Table 1**).

6
7 Positive associations between estradiol and angiotensinogen levels were observed in all
8 participants and were of greater magnitude in postmenopausal women on HT than those not on
9 HT and men (postmenopausal women on HT: $r = 0.44$, $p < 0.0001$; postmenopausal women not
10 on HT: $r = 0.09$, $p = 0.0002$; and men: $r = 0.07$, $p = 0.0003$). In the regression model presented in
11 **Figure 3**, the association between estradiol and angiotensinogen differs by specific group (men,
12 postmenopausal women not on HT, and postmenopausal women on HT). Using the model, we
13 compared angiotensinogen levels at the average estradiol levels for each group. At the average
14 log-estradiol level for men, angiotensinogen was 18.2 $\mu\text{g}/\text{mL}$ with a 95% confidence interval of
15 (18.0, 18.4). At the average log-estradiol level for women not on HT it was 20.8 $\mu\text{g}/\text{mL}$ with a
16 CI of (20.6, 21.1). At the average log-estradiol levels for postmenopausal women on HT it was
17 33.9 $\mu\text{g}/\text{mL}$ with a CI of (33.4, 34.5). For the same estradiol level, 0.2 nmol/L (mean for entire
18 cohort), men had a mean circulating angiotensinogen level of 18.7 $\mu\text{g}/\text{mL}$, postmenopausal
19 women not on HT had a mean angiotensinogen level of 19.5 $\mu\text{g}/\text{mL}$, and postmenopausal
20 women on HT had a mean angiotensinogen level of 33.9 $\mu\text{g}/\text{mL}$ (**Figure 3**).

21
22 An estimate one standard deviation (SD) higher log-estradiol level was associated with 0.195
23 SD, 0.585 SD, and 1.716 SD higher log-angiotensinogen (95% CI: 0.169, 0.220) in men,

1 postmenopausal women not on HT, and postmenopausal women on HT, respectively (**Table 2**).
2 Indicating smaller differences in angiotensinogen for the same amount of change in estradiol in
3 men and postmenopausal women not on HT as compared to those on HT (**Table 2, Figure 3**).

4
5 To further examine if the differences in the association between estrogen and angiotensinogen
6 between men, postmenopausal women not on HT and postmenopausal women on HT, we
7 adjusted the model described in **Table 2** for variables with univariable model R^2 values greater
8 than 0.025 (**Supplemental Table 2**). Following adjustment for race / ethnicity, BMI, total
9 cholesterol, hs-CRP, total testosterone, DHEA, and SHBG, the model coefficients for sex, HT,
10 and estradiol changed little in terms of direction or magnitude (**Supplemental Table 3**). The
11 proportion of the variance in angiotensinogen explained by estrogen, sex and HT status alone is
12 43.5%; increases to 48.0% with the addition of the variables noted above (**Table 2 and**
13 **Supplemental Table 3**) and the partial R^2 values for estradiol changed little following model
14 adjustment (**Supplemental Table 4**).

15
16 Different formulations of HT, only with estrogen or combined estrogen/progesterone, showed
17 similar levels of angiotensinogen with median value of 36.0 $\mu\text{g/mL}$ (95% CI: 32.7, 40.5) and
18 36.7 $\mu\text{g/mL}$ (95% CI: 33.7, 40.5), respectively. In addition, the duration of HT use was not
19 associated with angiotensinogen levels.

20
21 In the mediation analysis, we examined the role of angiotensinogen in explaining the relationship
22 between HT and blood pressure/ prevalent hypertension. The indirect effect of HT mediated
23 through angiotensinogen levels was associated with increased systolic BP ($\beta = 1.24$, $p = 0.040$)

1 and odds of hypertension (OR = 1.065, $p < 0.001$). The total effect of HT slightly increased the
2 odds of hypertension (OR = 1.082, $p < 0.001$) (**Table 3**).

3

4 **DISCUSSION**

5 The key findings of this study are as follows: (1) across all race/ethnicity groups, median
6 angiotensinogen levels were highest in postmenopausal women on HT, as compared to
7 postmenopausal women not on HT and men; (2) estrogen, sex and HT status alone accounts for
8 43.5% of variance in circulating angiotensinogen levels; (3) the indirect effect of HT mediated
9 through angiotensinogen levels increases systolic blood pressure and the odds of hypertension,
10 but did not have an impact on diastolic BP. These findings highlight the impact of
11 postmenopausal HT on circulating angiotensinogen levels, and the potential effect of HT on
12 prevalent hypertension through angiotensinogen levels.

13

14 Despite the availability of effective antihypertensive treatments, nearly half of patients with
15 hypertension fail to achieve BP goals recommended by guidelines. The pursuit of novel
16 antihypertensive therapies includes the development of antisense oligonucleotides (ASOs) and
17 small interfering RNA (siRNA), designed to reduce angiotensinogen secretion^{2,3,8}. Clinical trials
18 with ASO in Phase 1 (NCT03101878) on healthy volunteers and Phase 2 on patients with mild
19 (NCT03714776) and uncontrolled (NCT04083222) hypertension demonstrated favorable safety
20 and tolerability. These trials also showed targeted reductions in angiotensinogen levels, resulting
21 in significant decreases in both systolic and diastolic BP without compromising renal function or
22 increasing cardiovascular risk⁷. Similarly, Phase 1 trials with siRNA (NCT03934307) in
23 uncontrolled hypertension have shown promise in reducing blood pressure without worsening

1 renal function^{8,31,32}. Phase II trials assessing efficacy and optimal dosing are currently underway,
2 with a predicted completion by 2025. Understanding the determinants of angiotensinogen levels,
3 including sex hormones, race, sex, and menopausal status may influence the efficacy of this new
4 class of therapeutics.

5
6 Consistent with our results, previous studies demonstrated that postmenopausal estrogen therapy
7 was associated with increased angiotensinogen plasma concentrations^{16,33}. The role of
8 exogenous estrogen in stimulating *AGT* gene expression or secretion have been demonstrated in
9 animal models and hepatic cell line^{34–36}. In addition Schunkert et al.¹⁶ found increased
10 angiotensinogen levels to a similar extent in women taking formulations that contained only
11 estrogen or estrogen/progestin combination, both being significantly higher compared with
12 women without HT. Although there are recognized sex differences in blood pressure regulation
13 as well as cardiovascular disease susceptibility, onset, prevalence, clinical presentation,
14 pathophysiology, treatment responses and outcomes, the effects of exogenous estrogen on
15 angiotensinogen and its downstream metabolites, and consequently on blood pressure are limited
16^{16,37}. Trainor et al. (2023)¹³, using the same cohort of the present study, reported positive
17 associations between angiotensinogen and blood pressure/prevalent hypertension.

18
19 The effect of HT on prevalent hypertension, evidenced by mediation analysis, indicates that HT
20 indirectly increases the odds of prevalent hypertension via increased angiotensinogen, which
21 contributes to the total effect of HT on hypertension (**Central Illustration**). In systolic BP, this
22 indirect effect was counterbalanced by HT direct effects (independent of angiotensinogen) that
23 decrease systolic BP. This data suggests that the blood pressure effects of HT may be clinically

1 exploited by silencing the angiotensinogen mediated indirect blood pressure raising properties of
2 HT with newly developed therapeutics that directly target angiotensinogen production ².
3
4 Previous studies have evaluated the relationship between HT use and the development of
5 hypertension. The Women’s Health Initiative I (WHI I, [NCT00000611](#)], a randomized controlled
6 trial (RCT) assessing primary prevention in 16,608 participants, observed an increase in systolic
7 blood pressure among postmenopausal women using combined estrogen/progestin therapy ³⁸.
8 This is consistent with other prospective studies in normotensive postmenopausal women ^{39,40}.
9 Conversely, the Kronos Early Estrogen Prevention Study (KEEPS, [NCT00154180](#)), a RCT with
10 727 participants reported a neutral effect of HT on systolic blood pressure ⁴¹. In postmenopausal
11 women with preexisting hypertension, randomized prospective studies with sample size less than
12 100 demonstrated that the HT use was associated with both a decrease ^{42,43} and neutral ⁴⁴ effects
13 on blood pressure. Notably, the Heart and Estrogen/progestin Replacement Study I (HERS I,
14 [NCT00319566](#)) (RCT, n=2763) found no significant association between HT and the incidence
15 of myocardial infarction (MI) or stroke/transient ischemic attack in postmenopausal women with
16 established coronary disease ⁴⁵. However, the WHI I study observed higher stroke rates in the
17 HT group compared to the placebo ³⁸. A meta-analysis of 19 randomized controlled trials,
18 encompassing data from 40,410 postmenopausal women, furnished evidence that HT does not
19 affect the incidence of MI for either primary or secondary prevention but lead to a greater risk of
20 strokes ⁴⁶. Given that HT status was one of the major determinants of angiotensinogen levels in
21 our study, further investigations are warranted to elucidate the specific interactions between HT,
22 angiotensinogen, and the development of hypertension and hypertension-related cardiovascular
23 diseases (e.g., stroke).

1
2 Study limitations: There are limitations to this study. First, we restricted our sample to
3 postmenopausal women as both sex hormone levels and cardiovascular risk differ between pre-
4 and postmenopausal women, and there were relatively few pre-menopausal women in MESA
5 (17%), which would limit analyses in this subset. Second, route and dosage of HT therapy was
6 not available for this analysis, both of which may impact on angiotensinogen levels. Third, sex
7 hormones in MESA were not measured using the current gold standard of mass spectrometry but
8 rather using radioimmunoassay and thus might be prone to measurement error.

9
10 **CONCLUSIONS**
11 Angiotensinogen and estrogen levels showed a positive correlation that differ in magnitude
12 between sexes, with the strongest association evidenced in postmenopausal women on HT. We
13 observed evidence the HT indirectly increase systolic BP and odds of hypertension by increasing
14 angiotensinogen while lowering systolic BP via angiotensinogen independent direct effects. This
15 furthers our understanding of the implications of HT on angiotensinogen and BP in
16 postmenopausal women which may influence the utility of a new class of therapeutics designed
17 to directly reduce the production of angiotensinogen.

18
19 **SOURCES OF FUNDING**
20 This research was supported by an Institutional Development Award (IDeA) from the National
21 Institute of General Medical Sciences (NIGMS) of the National Institutes of Health under grant
22 number P20GM103451 and a Research Enhancement Award to PT from NIGMS under grant

1 number SC1GM139730. Additional support for this research, including sample processing and
2 angiotensinogen measurements was provided by Ionis Pharmaceuticals, Inc.

3
4 This research was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-
5 95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161,
6 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004,
7 N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-
8 95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants
9 UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for
10 Advancing Translational Sciences (NCATS). The authors thank the other investigators, the staff,
11 and the participants of the MESA study for their valuable contributions. A full list of
12 participating MESA investigators and institutions can be found at <http://www.mesa-nhlbi.org>.
13 This paper has been reviewed and approved by the MESA Publications and Presentations
14 Committee.

15

16 **DISCLOSURES**

17 ST is a co-inventor and receives royalties from patents owned by University of California San
18 Diego (UCSD) and is a co-founder and has an equity interest in Oxitope, LLC and Kleanthi
19 Diagnostics, LLC and has a dual appointment at UCSD and Ionis Pharmaceuticals. Although
20 these relationships have been identified for conflict-of-interest management based on the overall
21 scope of the project, the research findings included in this publication may not necessarily relate
22 to the interests of the above companies. The terms of this arrangement have been reviewed and
23 approved by the University of California, San Diego in accordance with its conflict-of-interest

1 policies. ESM is employee of Ionis Pharmaceuticals. The other authors have reported that they
2 have no relationships relevant to this work to disclose.

3

4 **DATA AVAILABILITY**

5 Interested investigators may request access to the data by contacting the MESA data
6 coordinating center (chscweb@u.washington.edu).

7

REFERENCES

- 8 1. Martyniak A, Tomasik PJ. A New Perspective on the Renin-Angiotensin System.
9 *Diagnostics*. 2022;13(1):16.
- 10 2. Kahlon T, Carlisle S, Otero Mostacero D, Williams N, Trainor P, DeFilippis AP.
11 Angiotensinogen. *JACC: Heart Failure*. 2022;10(10):699–713.
- 12 3. Cruz-López EO, Ye D, Wu C, Lu HS, Ujil E, Mirabito Colafella KM, Danser AHJ.
13 Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease.
14 *Hypertension*. 2022;79(10):2115–2126.
- 15 4. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of
16 angiotensin-converting enzyme inhibitors in cardiac and vascular protection. *Circulation*.
17 1994;90(4):2056–2069.
- 18 5. Yusuf S, Pepine CJ, Garces C, Pouleur H, Rousseau M, Salem D, Kostis J, Benedict C,
19 Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients
20 with low ejection fractions. *The Lancet*. 1992;340(8829):1173–1178.
- 21 6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman
22 EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, et al. Effect
23 of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after
24 Myocardial Infarction: Results of the Survival and Ventricular Enlargement Trial. *New England*
25 *Journal of Medicine*. 1992;327(10):669–677.
- 26 7. Morgan ES, Tami Y, Hu K, Brambatti M, Mullick AE, Geary RS, Bakris GL, Tsimikas S.
27 Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx. *JACC: Basic to Translational*
28 *Science*. 2021;6(6):485–496.
- 29 8. Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee
30 S, Sweetser MT, Bakris GL. Zilebesiran, an RNA Interference Therapeutic Agent for
31 Hypertension. *New England Journal of Medicine*. 2023;389(3):228–238.
- 32 9. Dickson ME, Sigmund CD. Genetic Basis of Hypertension: Revisiting Angiotensinogen.
33 *Hypertension*. 2006;48(1):14–20.
- 34 10. Dickson ME, Zimmerman MB, Rahmouni K, Sigmund CD. The –20 and –217 Promoter
35 Variants Dominate Differential Angiotensinogen Haplotype Regulation in Angiotensinogen-
36 Expressing Cells. *Hypertension*. 2007;49(3):631–639.
- 37 11. Lu H, Cassis LA, Kooi CWV, Daugherty A. Structure and functions of angiotensinogen.
38 *Hypertension Research*. 2016;39(7):492–500.

- 1 12. White MC, Fleeman R, Arnold AC. Sex differences in the metabolic effects of the renin-
2 angiotensin system. *Biology of Sex Differences*. 2019;10(1):31.
- 3 13. Trainor PJ, Brambatti M, Carlisle SM, Mullick AE, Shah SJ, Kahlon T, Mostacero DO,
4 Mousavi H, Morgan ES, Tami Y, Michos ED, Ouyang P, Tsimikas S, DeFilippis AP. Blood
5 Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis
6 (MESA). *Journal of the American College of Cardiology*. 2023;81(13):1248–1259.
- 7 14. Kang AK, Duncan JA, Cattran DC, Floras JS, Lai V, Scholey JW, Miller JA. Effect of oral
8 contraceptives on the renin angiotensin system and renal function. *American Journal of*
9 *Physiology-Regulatory, Integrative and Comparative Physiology*. 2001;280(3):R807–R813.
- 10 15. Harvey PJ, Wing LM, Savage J, Molloy D. The effects of different types and doses of
11 oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin–
12 angiotensin system in normotensive postmenopausal women: *Journal of Hypertension*.
13 1999;17(3):405–411.
- 14 16. Schunkert H, Danser AHJ, Hense H-W, Derkx FHM, Ku`rzinger S, Riegger GAJ. Effects of
15 Estrogen Replacement Therapy on the Renin-Angiotensin System in Postmenopausal Women.
16 *Circulation*. 1997;95(1):39–45.
- 17 17. Harvey PJ, Morris BL, Miller JA, Floras JS. Estradiol Induces Discordant Angiotensin and
18 Blood Pressure Responses to Orthostasis in Healthy Postmenopausal Women. *Hypertension*.
19 2005;45(3):399–405.
- 20 18. Bild DE. Multi-Ethnic Study of Atherosclerosis: Objectives and Design. *American Journal*
21 *of Epidemiology*. 2002;156(9):871–881.
- 22 19. Blaha MJ, DeFilippis AP. Multi-Ethnic Study of Atherosclerosis (MESA). *Journal of the*
23 *American College of Cardiology*. 2021;77(25):3195–3216.
- 24 20. Ying W, Zhao D, Ouyang P, Subramanya V, Vaidya D, Ndumele CE, Sharma K, Shah SJ,
25 Heckbert SR, Lima JA, deFilippi CR, Budoff MJ, Post WS, Michos ED. Sex Hormones and
26 Change in N-Terminal Pro-B-Type Natriuretic Peptide Levels: The Multi-Ethnic Study of
27 Atherosclerosis. *The Journal of Clinical Endocrinology & Metabolism*. 2018;103(11):4304–
28 4314.
- 29 21. Zhao D, Guallar E, Ouyang P, Subramanya V, Vaidya D, Ndumele CE, Lima JA, Allison
30 MA, Shah SJ, Bertoni AG, Budoff MJ, Post WS, Michos ED. Endogenous Sex Hormones and
31 Incident Cardiovascular Disease in Post-Menopausal Women. *Journal of the American College*
32 *of Cardiology*. 2018;71(22):2555–2566.
- 33 22. Subramanya V, Zhao D, Ouyang P, Lima JA, Vaidya D, Ndumele CE, Bluemke DA, Shah
34 SJ, Guallar E, Nwabuo CC, Allison MA, Heckbert SR, Post WS, Michos ED. Sex hormone
35 levels and change in left ventricular structure among men and post-menopausal women: The
36 Multi-Ethnic Study of Atherosclerosis (MESA). *Maturitas*. 2018;108:37–44.
- 37 23. Subramanya V, Ambale-Venkatesh B, Ohyama Y, Zhao D, Nwabuo CC, Post WS, Guallar
38 E, Ouyang P, Shah SJ, Allison MA, Ndumele CE, Vaidya D, Bluemke DA, Lima JA, Michos
39 ED. Relation of Sex Hormone Levels With Prevalent and 10-Year Change in Aortic
40 Distensibility Assessed by MRI: The Multi-Ethnic Study of Atherosclerosis. *American Journal*
41 *of Hypertension*. 2018;31(7):774–783.
- 42 24. R Core Team. R: A Language and Environment for Statistical Computing. *R Foundation for*
43 *Statistical Computing*. 2020.
- 44 25. Kim S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients.
45 *Communications for Statistical Applications and Methods*. 2015;22(6):665–674.

- 1 26. Efron B, Hastie T. *Computer age statistical inference: algorithms, evidence, and data*
2 *science*. Student edition. Cambridge, United Kingdom New York, NY Port Melbourne, Australia
3 New Delhi, India Singapore: Cambridge University Press; 2021.
- 4 27. Lenth R. Emmeans: Estimated Marginal Means, Aka Least Square Means. 2020.
- 5 28. Wickham H, Francois R, Henry L, Muller K. dplyr: A Grammar of Data Manipulation (R
6 package). 2020.
- 7 29. Wickham. *Ggplot2*. New York, NY: Springer Science+Business Media, LLC; 2016.
- 8 30. Tingley, D., Yamamoto, T., Hirose, K., Imai, K., Keele, L. Mediation: R package for Causal
9 Mediation Analysis. 59(5):1–38.
- 10 31. Khan RS, Frishman WH. Zilebesiran: A Promising Antihypertensive Therapy Inhibiting
11 Angiotensinogen Synthesis. *Cardiology in Review*. 2024.
- 12 32. Liuzzo G, Volpe M. Silencing liver angiotensinogen synthesis as a novel approach to
13 hypertension management: promises and challenges. *European Heart Journal*.
14 2023;44(40):4217–4219.
- 15 33. Seely EW, Brosnihan KB, Jeunemaitre X, Okamura K, Williams GH, Hollenberg NK,
16 Herrington DM. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin
17 system, blood pressure and renal blood flow in postmenopausal women: *CEE, droloxifene and*
18 *the RAAS*. *Clinical Endocrinology*. 2004;60(3):315–321.
- 19 34. Chang E, Perlman AJ. Multiple Hormones Regulate Angiotensinogen Messenger
20 Ribonucleic Acid Levels in a Rat Hepatoma Cell Line. *Endocrinology*. 1987;121(2):513–519.
- 21 35. Voigt J, Koster H. Induction of Plasma Proangiotensin by Steroid Hormones in
22 Nephrectomized Rats. *European Journal of Biochemistry*. 1980;110(1):57–65.
- 23 36. AlSiraj Y, Woolley C, Thatcher SE, Cassis LA. Sex Differences and the Role of the Renin-
24 Angiotensin System in Atherosclerosis and Abdominal Aortic Aneurysms. In: *Sex Differences in*
25 *Cardiovascular Physiology and Pathophysiology*. Elsevier; 2019:167–184.
- 26 37. Medina D, Mehay D, Arnold AC. Sex differences in cardiovascular actions of the renin-
27 angiotensin system. *Clinical Autonomic Research*. 2020;30(5):393–408.
- 28 38. Writing Group For The Women’s Health Initiative Investigators. Risks and Benefits of
29 Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the
30 Women’s Health Initiative Randomized Controlled Trial. *JAMA: The Journal of the American*
31 *Medical Association*. 2002;288(3):321–333.
- 32 39. Chiu CL, Lujic S, Thornton C, O’Loughlin A, Makris A, Hennessy A, Lind JM.
33 Menopausal Hormone Therapy Is Associated with Having High Blood Pressure in
34 Postmenopausal Women: Observational Cohort Study. Jose PA, ed. *PLoS ONE*.
35 2012;7(7):e40260.
- 36 40. Madika A-L, MacDonald CJ, Fournier A, Mounier-Vehier C, Béraud G, Boutron-Ruault M-
37 C. Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen
38 administration and progestogens in the E3N cohort. *Menopause*. 2021;28(11):1204–1208.
- 39 41. Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling
40 NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, et al.
41 The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? *Menopause*.
42 2019;26(9):1071–1084.
- 43 42. Affinito P, Palomba S, Bonifacio M, Fontana D, Izzo R, Trimarco B, Nappi C. Effects of
44 hormonal replacement therapy in postmenopausal hypertensive patients. *Maturitas*.
45 2001;40(1):75–83.

- 1 43. Kaya C, Dinçer Cengiz S, Cengiz B, Akgün G. The long-term effects of low-dose 17beta-
2 estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure
3 in hypertensive postmenopausal women: a 1-year randomized, prospective study. *Climacteric:*
4 *The Journal of the International Menopause Society*. 2006;9(6):437–445.
- 5 44. Kornhauser C, Malacara JM, Garay ME, Pérez-Luque EL. The effect of hormone
6 replacement therapy on blood pressure and cardiovascular risk factors in menopausal women
7 with moderate hypertension. *Journal of Human Hypertension*. 1997;11(7):405–411.
- 8 45. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized
9 trial of estrogen plus progestin for secondary prevention of coronary heart disease in
10 postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research
11 Group. *JAMA*. 1998;280(7):605–613.
- 12 46. Boardman HM, Hartley L, Eisinga A, Main C, Roqué I Figuls M, Bonfill Cosp X, Gabriel
13 Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-
14 menopausal women. Cochrane Heart Group, ed. *Cochrane Database of Systematic Reviews*.
15 2015;2015(8).
- 16

FIGURE LEGENDS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Graphical Abstract: Association between angiotensinogen and sex, and its clinical implications in postmenopausal women on hormone therapy (HT).

Figure 1: Participant inclusion/exclusion in study.

HT, hormone therapy.

Figure 2: Distribution of circulating angiotensinogen levels by sex, race/ethnicity, and hormone therapy (HT) status in postmenopausal (PM) women. Boxplot shows 25th percentile, median, and 75th percentile. Table shows median and quartile values (25th and 75th percentiles).

Figure 3: Linear relationship between log-transformed estradiol and log-transformed angiotensinogen levels stratified by sex and hormone therapy (HT) status with density curves in the margin showing the distribution of each by group. Regression lines are shown based on an interaction effect between sex and HT. Each dot represents a participant.

PM, postmenopausal women.

1 **Table 1:** Cohort characteristics of the 5,171 MESA participants stratified by sex and Hormone Therapy
 2 (HT). Percentages presented are the number of participants in each row variable over the total number in
 3 each column.

4

Characteristic	Men (N = 2736)	PM not on HT (N = 1675)	PM on HT (N = 760)
Mean age ± SD, years	62.6 ± 10.2	66.2 ± 9.2	62.6 ± 8.7
Race/Ethnicity, n (%)			
White	1037 (37.9)	487 (29.1)	410 (53.9)
Black	737 (26.9)	524 (31.3)	177 (23.3)
Chinese	351 (12.8)	248 (14.8)	56 (7.4)
Hispanic	611 (22.3)	416 (24.8)	117 (15.4)
Diabetes, n (%)	383 (14.0)	234 (14.0)	65 (8.6)
Mean BMI ± SD, kg/m ²	27.8 ± 4.4	28.9 ± 6.0	28.0 ± 5.9
Mean total cholesterol ± SD, mg/dL	188.0 ± 35.1	202.7 ± 36.5	199.4 ± 33.5
Mean HDL cholesterol ± SD, mg/dL	45.1 ± 11.8	54.7 ± 14.5	61.2 ± 16.8
Mean LDL cholesterol ± SD, mg/dL	116.5 ± 31.1	122.6 ± 32.7	110.3 ± 29.6
Mean systolic BP ± SD, mmHg	126.1 ± 19.4	131.3 ± 24.0	126.9 ± 22.0
Mean diastolic BP ± SD, mmHg	75.1 ± 9.4	69.6 ± 10.4	68.3 ± 9.9
Hypertension, n (%)	1185 (43.3)	873 (52.1)	374 (49.2)
Any hypertension medication, n (%)	997 (36.4)	694 (41.4)	327 (43.1)
Any lipid lowering medication, n (%)	454 (16.6)	325 (19.4)	143 (18.8)
Current aspirin use, n (%)	787 (28.8)	391 (23.4)	199 (26.2)
Smoking history, n (%)			
Never	1115 (40.9)	1066 (63.8)	365 (48.3)
Former	1229 (45.1)	432 (25.9)	305 (40.3)
Current	383 (14.0)	172 (10.3)	86 (11.4)
Alcohol history, n (%)			
Never	279 (10.3)	601 (36.1)	168 (22.4)
Former	748 (27.5)	360 (21.6)	156 (20.8)
Current	1690 (62.2)	704 (42.3)	426 (56.8)
Median hs-CRP [Q1, Q3], mg/L	1.390 [0.690, 3.060]	2.210 [0.978, 4.695]	3.515 [1.490, 6.945]
Median Creatinine [Q1, Q3], mg/dL	1.02 [0.92, 1.22]	0.82 [0.72, 0.92]	0.82 [0.72, 0.92]
Mean eGFR ± SD	75.7 ± 16.0	71.8 ± 15.8	71.6 ± 15.0
Total testosterone [Q1, Q3], nmol/L	14.12 [11.31, 17.67]	0.94 [0.62, 1.39]	0.76 [0.45, 1.18]
Dehydroepiandrosterone [Q1, Q3], nmol/L	12.4 [9.1, 17.0]	10.9 [7.5, 15.2]	8.7 [6.0, 12.7]
Sex Hormone Binding Globulin [Q1, Q3], nmol/L	41.2 [31.5, 53.0]	50.6 [37.2, 70.3]	103.0 [63.1, 163.2]
Estradiol [Q1, Q3], nmol/L	0.114 [0.088, 0.139]	0.059 [0.040, 0.081]	0.231 [0.128, 0.356]

5 Note: data are shown as mean and standard deviation (SD), n (%), or median [Q1, Q3].
 6 BMI, body mass index; BP, blood pressure; HDL, high-density-lipoprotein; hs-CRP, high-sensitivity C-reactive
 7 protein; LDL, low-density-lipoprotein; eGFR; Q1, first quartile (25th percentile); Q3, third quartile (75th percentile).
 8
 9

10

1 **Table 2:** Un-adjusted model for predicting angiotensinogen from estradiol, in men, post-menopausal
2 women not on HT, and post-menopausal women on HT.

3
4 Note: Each analyte was log-transformed and then scaled to have mean zero and standard deviation 1. The
5 model coefficients are thus in terms of standard deviation units. Men were considered the reference level
6 for sex.

7

Variable	Estimate	(95% CI)	p-value
Intercept	-0.443	(-0.471, -0.414)	<0.0001
PM not on HT	0.585	(0.534, 0.636)	<0.0001
PM on HT	1.716	(1.652, 1.781)	<0.0001
Estradiol	0.195	(0.169, 0.220)	<0.0001

$R^2 = 0.435$

†Estradiol concentrations were log-transformed, centered, and standard deviation scaled.

PM: postmenopausal women.

HT: hormone therapy

8

9

1 **Table 3.** Direct, indirect, and total effects of HT on systolic blood pressure (BP), diastolic BP, and
 2 hypertension with angiotensinogen as a mediator.

3
 4 Note: Angiotensinogen levels have been log-transformed and standardized. Models to regress
 5 angiotensinogen on HT were adjusted for age, race/ethnicity, BMI, smoking history, and use of any
 6 hypertension medication. Models to regress blood pressure/ hypertension on HT were adjusted for
 7 angiotensinogen levels, age, race/ethnicity, BMI, smoking history, and use of any hypertension
 8 medication (only for blood pressure).

9

Dependent Variable	Effects	Estimate	(95% CI)	p-value
Systolic BP	Direct Effect <i>HT → Systolic BP</i>	-1.19	(-3.36, 1.14)	0.306
	Indirect Effect <i>HT → Angiotensinogen → Systolic BP</i>	1.24	(0.357, 2.48)	0.040
	Total Effect	0.048	(-1.88, 1.87)	0.953
Diastolic BP	Direct Effect <i>HT → Diastolic BP</i>	-1.710	(-2.78, -0.55)	< 0.0001
	Indirect Effect <i>HT → Angiotensinogen → Diastolic BP</i>	0.472	(-0.16, 1.08)	0.126
	Total Effect	-1.234	(-2.13, -0.27)	0.014
Hypertension	Direct Effect <i>HT → Hypertension</i>	1.016	(0.97, 1.06)	0.530
	Indirect Effect <i>HT → Angiotensinogen → Hypertension</i>	1.065	(1.04, 1.09)	< 0.001
	Total Effect	1.082	(1.04, 1.13)	< 0.001

BMI, body mass index; HT, hormone therapy; BP, blood pressure.

10

11

12









